← Eichor
Condition: Iga Nephropathy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Iga Nephropathy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Raman Spectroscopy Diagnosis of Kidney Diseases
Phase N/A · 1 location(s) · Zunsong Wang · NCT06760845Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT06792799A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
Phase 2 · 26 location(s) · Novartis Pharmaceuticals · NCT07146906Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Phase 4 · 38 location(s) · Calliditas Therapeutics AB · NCT06712407Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Phase 3 · 1 location(s) · Air Force Military Medical University, China · NCT05510323Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Phase 2 · 18 location(s) · Novartis Pharmaceuticals · NCT06797518Study of BHV-1400 in IgA Nephropathy
Phase 1 · 15 location(s) · Biohaven Therapeutics Ltd. · NCT07054684Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
Phase N/A · 1 location(s) · Chinese PLA General Hospital · NCT07585981CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07586267RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06926244Efficacy and Safety of Telitacicept in IgAN
NA · 1 location(s) · Ruijin Hospital · NCT06654596Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
NA · 1 location(s) · Botkin Hospital · NCT07056595A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Phase 2 · 1 location(s) · Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijin · NCT07305974A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Phase 2 · 1 location(s) · Chengdu Suncadia Medicine Co., Ltd. · NCT07582133Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)
NA · 1 location(s) · University Hospital, Limoges · NCT07295808Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
Phase 2 · 2 location(s) · Mayo Clinic · NCT06676579Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Phase 3 · 251 location(s) · Biogen · NCT06935357IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT03001947Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Phase 2 · 34 location(s) · ADARx Pharmaceuticals, Inc. · NCT06989359Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
NA · 1 location(s) · Centre Hospitalier Universitaire de Besancon · NCT05791162Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study
Phase 2 · 7 location(s) · Centre Hospitalier Universitaire de Saint Etienne · NCT06350630A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT06952426CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Phase 3 · 9 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07390123A Phase 1 Study of CLYM116 in Normal Healthy Volunteers
Phase 1 · 1 location(s) · Climb Bio, Inc. · NCT07248865A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Phase 3 · 1 location(s) · Biocity Biopharmaceutics Co., Ltd. · NCT06819826Correlation of Microbiome and Metabonomics With IgA Nephropathy
Phase N/A · 5 location(s) · Guangdong Provincial People's Hospital · NCT05190848
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.